RELX Presents Strategy to Accelerate STM Revenue Growth
RELX reported 6% underlying revenue growth in its Scientific, Technical & Medical business for H1 2026, with adjusted operating profit up 8%. The segment contributed 28% of group revenue and 30% of profit. Elsevier saw a 20% rise in article submissions and 7% increase in published articles. The company aims to boost research publishing and product innovation to maintain profit growth ahead of revenue.
How this was made
The 30-second read
Why it matters
The half‑year growth beats prior expectations and may prompt analysts to raise forecasts.
Market read
Strong STM performance could lift RELX and peer stocks in the information‑services sector.
What to watch
Potential cost pressures from rising content acquisition costs are not addressed.
Background
RELX is a global provider of information and analytics services; its STM segment accounts for roughly a quarter of total revenue.
Ticker impact
RELX reported 6% underlying revenue growth and 8% operating profit increase in its Scientific, Technical & Medical segment for H1 2026.
likely upward pressure as market prices in the stronger-than-expected STM performance
First disclosure of half‑year numbers shows solid growth; no prior public data on these figures.
Market effects
Boosts outlook for the broader scientific, technical and medical publishing sector.
May support European information‑services stocks.
Highlights continued demand for research publishing worldwide.
Counterpoint
If growth slows in later quarters, the current rally could be short‑lived.
Key entities
- companyRELX
Global information and analytics provider

